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Abstract 
Background: Typhoid fever, caused by the human-restricted organism Salmonella Typhi (S. Typhi), is a major public 
health problem worldwide. Development of novel vaccines remains imperative, but is hampered by an incomplete 
understanding of the immune responses that correlate with protection.
Methods: Recently, a controlled human infection model was re-established in which volunteers received ~103 cfu 
wild-type S. Typhi (Quailes strain) orally. Twenty-one volunteers were evaluated for their cell-mediated immune (CMI) 
responses. Ex vivo PBMC isolated before and up to 1 year after challenge were exposed to three S. Typhi-infected 
targets, i.e., autologous B lymphoblastoid cell-lines (B-LCL), autologous blasts and HLA-E restricted AEH B-LCL cells. 
CMI responses were evaluated using 14-color multiparametric flow cytometry to detect simultaneously five intracel-
lular cytokines/chemokines (i.e., IL-17A, IL-2, IFN-g, TNF-a and MIP-1b) and a marker of degranulation/cytotoxic activity 
(CD107a).
Results: Herein we provide the first evidence that S. Typhi-specific CD8+ responses correlate with clinical outcome 
in humans challenged with wild-type S. Typhi. Higher multifunctional S. Typhi-specific CD8+ baseline responses were 
associated with protection against typhoid and delayed disease onset. Moreover, following challenge, development 
of typhoid fever was accompanied by decreases in circulating S. Typhi-specific CD8+ T effector/memory (TEM) with 
gut homing potential, suggesting migration to the site(s) of infection. In contrast, protection against disease was 
associated with low or no changes in circulating S. Typhi-specific TEM.
Conclusions: These studies provide novel insights into the protective immune responses against typhoid disease 
that will aid in selection and development of new vaccine candidates.
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Background
Typhoid fever constitutes a major global health problem, 
with an estimated 21.7 million cases and 200,000 deaths 
annually [1]. The development of improved vaccines is 
necessary, but advances have been delayed by a lack of 
knowledge of the immunological correlates of protec-
tion against Salmonella enterica serovar Typhi (S. Typhi). 
Since the causative agent of typhoid fever, S. Typhi, is a 
human-restricted bacteria [2], current knowledge is lim-
ited due to the difficulties associated with performing 
challenge studies in humans and the lack of adequate 
pre-clinical models that closely mimic typhoid fever.
Recently, a human challenge model was established by 
the Oxford Vaccine Group (OVG, University of Oxford) 
in which naïve participants ingested wild-type (wt) S. 
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Typhi (Quailes strain) [3, 4]. This controlled infection 
study was modeled after the human typhoid challenge 
studies performed in the 1960s at the University of Mar-
yland. The Maryland studies improved understanding 
of typhoid fever [5–8] and resulted in the initiation of 
the process to license the oral attenuated Ty21a typhoid 
vaccine [9], but did not identify the immunological cor-
relates of protection. Although substantial data are avail-
able on the immune responses after infection in the 
field or following vaccination, there are no studies that 
provide insights into the immunological status before 
wild-type infection and its possible effects on clinical 
outcome.
The re-establishment of the human challenge model 
with wt S. Typhi, and the use of cutting-edge multichro-
matic flow cytometry allowed us, for the first time, to 
investigate the pre-challenge immunological status and 
its correlation with the subsequent clinical outcome. 
Furthermore, it allowed the initiation of detailed studies 
of the kinetics and characteristics of the immunological 
responses occurring following infection with wt S. Typhi.
Several immunization studies with attenuated typhoid 
vaccine candidates suggested that cell-mediated immu-
nity (CMI), particularly CD8+ effector T cells, consti-
tute a major component in the control of typhoid fever 
[10, 11]. CD8+ T cells may be involved in destroying 
infected-host cells through cytolytic activity and/or 
production of cytokines (e.g., interferon (IFN)-γ, tumor 
necrosis factor (TNF)-α, interleukin (IL)-17) [12–22].
Recent research on the immune responses after oral 
immunization with Ty21a have revealed persistent mul-
tiphasic, multifunctional (simultaneous production of 
multiple cytokines) responses to antigenic presentation 
by class Ia HLA and by the more conserved and less poly-
morphic non-classical HLA-E molecules [13, 19, 20, 22].
In the present study we investigated the relation-
ship between S. Typhi-specific CD8+ T cell responses 
before exposure to wt S. Typhi and clinical outcome, i.e., 
whether the participants who were challenged developed 
disease or not. We also explored S. Typhi-specific CD8+ 
T cells responses following challenge, as well as their gut 
homing potential in relationship with typhoid diagnosis. 
Finally, we identified the dominant multifunctional S. 
Typhi-specific response patterns associated with clini-
cal outcome by evaluating the simultaneous production 
of macrophage inflammatory protein (MIP)-1β, IFN-γ, 
TNF-α, IL-2 and IL-17A, as well as the expression of the 
cytotoxicity degranulation marker CD107a [23]. These 
investigations provide evidence that baseline S. Typhi-
specific responses are related to clinical outcome after 
wt S. Typhi infection and provide novel insights into the 
immunological responses involved in protection follow-
ing natural infection and vaccination.
Methods
Participants and study design
Twenty-one healthy, male or female participants aged 
18–60 years were recruited by the Oxford vaccine Group, 
Department of Paediatrics, Oxford, UK, to participate in 
this dose-escalation study. Any participant with a history 
of typhoid fever or immunization against typhoid fever, 
or who lived in a typhoid-endemic region for longer than 
6 months, was excluded from participation. Only partici-
pants with low risk of becoming chronic carriers (includ-
ing those without gall stones, determined by ultrasound 
examination of the gallbladder) were included. Partici-
pants were challenged orally with a dose of 1–5  ×  103 
CFU of wt S. Typhi (Quailes strain) suspended in 
sodium bicarbonate. The S. Typhi Quailes strain, which 
was used extensively for human challenge studies in the 
1960s/1970s was developed by the University of Mary-
land and used to establish a master cell bank in Oxford. 
Participants were monitored closely throughout the 
study. A positive typhoid fever diagnosis was defined 
based on the following criteria: either a positive blood 
culture for Salmonella Typhi from day 5 post-challenge 
or, oral temperature ≥38  °C, persisting continuously 
for at least 12-h in the absence of anti-pyretic medica-
tion, occurring from 72-h after challenge. At the point of 
typhoid fever diagnosis (TD, as determined by S. Typhi 
bacteremia or development of a fever >38 °C for ≥12 h) 
participants were treated with a 2-week course of anti-
biotics (ciprofloxacin, 500 mg BD). Participants who did 
not developed typhoid fever (NoTD) received a 2-week 
course of antibiotics at day 14 post-challenge. Periph-
eral blood mononuclear cells (PBMC) obtained from 16 
selected participants based on cell availability were ana-
lyzed in these studies (Additional file 1: Table S1). These 
included all nine who were not diagnosed with typhoid 
(NoTD) and seven participants were diagnosed with 
typhoid (TD).
Ethics statement
Written informed consent was obtained and all pro-
cedures approved by National Research Ethic Service 
(NRES), Oxfordshire Research Ethics Comittee A (10/
H0604/53) and conducted in accordance with the prin-
ciples of the International Conference of Harmonisation 
Good Clinical Practice guidelines.
Specimen collection and isolation of PBMC
Blood was collected from each participant and rou-
tine blood hematology was assessed on alternate days 
after challenge and at typhoid diagnosis. PBMC were 
separated by Lymphoprep gradient centrifugation (Axis-
Shield, Oslo, Norway) cryopreserved in liquid nitrogen 
following standard techniques within 4 h of initial blood 
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draw within 4 h of initial blood draw and stored in liquid 
N2. Upon thawing, viability and recovery were measured 
using trypan blue exclusion and a Guava easyCyte™ flow 
cytometer (Merck KGaA, Darmstadt, Germany), and 
cells were rested overnight in complete RPMI (cRPMI: 
RPMI 1640 media (Gibco, Carlsbad, CA) supplemented 
with 100 U/mL penicillin (Sigma), 100 µg/mL streptomy-
cin (Sigma), 50 μg/mL gentamicin (Gibco), 2 mM l-glu-
tamine (Gibco), 10 mM HEPES buffer (Gibco) and 10 % 
heat-inactivated fetal bovine serum (Gemini Bioprod-
ucts, West Sacramento, CA) to serve as effector cells in 
CMI assays.
Stimulator cells
Autologous Epstein-Barr virus (EBV)-transformed 
lymphoblastoid cell line (B-EBV cells) and autologous 
blasts were generated from the PBMC of each participant 
isolated before challenge. B-EBV cells were obtained by 
incubation of the PBMC with EBV-containing superna-
tant from the B95-8 cell line (ATCC CRL1612) and cyclo-
sporine (0.5  ug/mL; Sigma-Aldrich, Saint-Louis, MO) 
at 37  °C with 5  % CO2 for 2–3  weeks. PHA-activated 
blasts were prepared by incubating PBMC with 1  μg/
ml PHA (Sigma-Aldrich, St. Louis, MO) in cRPMI for 
24 h, followed by washing and culture in cRPMI contain-
ing 20  IU/ml recombinant human IL-2 (rhIL-2; Roche, 
Indianapolis, IN) for 7  days. The HLA classical class 
I-defective B cell line 721.222.AEH which expresses non-
classical class-I HLA-E molecules was provided by Dr. D. 
Geraghty [14] and cultured in cRPMI supplemented with 
200 mU/ml hygromycin B (Sigma-Aldrich).
S. Typhi infection of stimulator cells
Stimulating cells were infected by incubation for 3  h at 
37  °C with wt-S. Typhi strain ISP1820 at a multiplicity 
of infection of 7:1 in RPMI without antibiotics, washed 
three times with cRMPI and incubated overnight with 
cRPMI containing 150  μg/ml gentamicin. Cells were 
washed and infection with S. Typhi was confirmed by 
staining with anti-Salmonella common structural Ag 
(CSA-1) (Kierkegaard and Perry, Gaithersburg, MD) and 
analysis by flow cytometry as previously described [10].
Ex‑vivo stimulation of effector cells
PBMC were thawed and rested in cRPMI overnight 
at 37  °C in 5  % CO2 before stimulation with S. Typhi-
infected stimulating cells. Uninfected target cells and 
Staphylococcal enterotoxin B (SEB; 10 μg/ml) were used 
as negative and positive controls, respectively. Target 
cells were gamma-irradiated (6000  rad) and co-cultured 
with PBMC (effector:stimulator ratio 5:1) in the presence 
of the FITC-conjugated anti-CD107a (BD Biosciences) 
monoclonal antibody (mAb). After 2  h, the protein 
transport blockers monensin (1  µg/ml, Sigma) and bre-
feldin A (2 µg/ml; Sigma) were added to the PBMC and 
cells were incubated overnight at 37  °C in 5 % CO2. For 
the kinetics analysis, because of the variable responsive-
ness at baseline in the different participants, the net val-
ues (day x post-challenge—day 0) were used to normalize 
the data.
Immunostaining with 14‑color panel mAbs
Following stimulation, PBMC were harvested, washed 
in 1X PBS and stained for dead-cell discrimination using 
Yellow Live/Dead viability kit (Invitrogen, Carlsbad, CA). 
Cells were then washed with wash buffer (PBS 1 % FCS) 
and non-specific Fc receptor binding was blocked with 
human immunoglobulin (3 µg/mL; Sigma) for 10 min at 
room temperature (RT). Cells were surface stained with 
mAbs against CD14-BV570 (M5E2, Biolegend), CD19-
BV570 (HIB19, Biolegend), CD3-BV650 (OKT3, Biole-
gend), CD4-PE-Cy5 (RPA-T4, BD), CD8-PerCP-Cy5.5 
(SK1, BD), CD45RA-biotin (HI100, BD), CD62L-APC-
A780 (DREG-56, Ebioscience) and integrin α4β7-A647 
(ACT1; conjugated in house) at 4  °C for 30  min. Cells 
were washed with wash buffer and stained with streptavi-
din (SAV)-Qdot800 (Invitrogen) at 4 °C for 30 min. Cells 
were then fixed and permeabilized with Fix and Perm 
buffers (Invitrogen). Intracellular staining was then per-
formed with mAbs against CD69-ECD (TP1.55.3, Beck-
man Coulter), IFN-γ-PE-Cy7 (B27, BD), TNF-α-A700 
(MAb11, BD), IL-2-BV605 (MQ1-17H12, Biolegend), IL-
17A-BV421 (BL168, Biolegend) and MIP-1β-PE (IC271P, 
R&D) at 4 °C for 30 min. Cells were washed with PBS 1 % 
FCS, fixed in 1  % paraformaldehyde (PFA) and stored 
at 4  °C until analyzed. Samples were acquired by flow 
cytometry using a customized LSRII flow cytometer 
(BD Biosciences) and analyzed using Winlist v7.0 (Ver-
ity Software House, Topsham, ME). CD8+ T cells were 
selected after a gating strategy involving the exclusion of 
dead cells and CD3−, CD14+ and CD19+ cells. Abso-
lute numbers of CD3 +, CD8+, CD4+ cells and CD8+ 
memory subsets cells were calculated by using percent-
ages obtained from flow cytometry analysis related to the 
absolute number of lymphocytes determined by routine 
blood count. S. Typhi-specific responses were expressed 
as net percentage of positive cells (background after 
stimulation with uninfected cells were subtracted from 
values obtained with S. Typhi-infected stimulators).
Statistical analyses
Mann–Whitney tests and linear regression analysis were 
performed using Prism v7.02 (Graphpad software, La 
Jolla, CA). Areas under the curve were measured using 
the trapezoidal method (GraphPad Prism v7.02). P val-
ues <0.05 were considered significant. Some comparisons 
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were based on multiple outcomes from the same indi-
vidual as indicated in the text. In these cases the same 
individual provided information on cytokine production 
and/or CD107a expression levels after stimulation with 
three types of stimulations (EBV-B, AEH, and blasts), and 
these responses we evaluated with regard to clinical out-
come (i.e., TD vs. NoTD patients). In these analyses we 
accounted for the correlation between multiple outcomes 
from the same person using a mixed effects model fit by 
maximum likelihood, including a random effect for per-
son, using SAS 9.3 (Cary, NC). We found by performing 
simulations that this correlation model provided more 
accurate statistical inference than models with more 
complex correlation structure given the small sample 
sizes.
Results
Baseline S. Typhi‑specific CD8+ T cell responses correlate 
with clinical outcome after challenge
CD8+ T cells have been reported to be a major compo-
nent of the CMI response against S. Typhi [11–13, 16, 22]. 
Thus, we first explored whether CD8+ T cell responses 
in healthy participants at baseline could predict clinical 
outcome after challenge with 1–5  ×  103 CFU of wt S. 
Typhi. All nine volunteers who did not develop typhoid 
disease (NoTD group) and seven participants who did 
develop typhoid disease (TD group) were evaluated. 
Peripheral blood mononuclear cells (PBMC) isolated 
from volunteers before challenge (day 0) were stimu-
lated in  vitro with S. Typhi-infected autologous B-EBV, 
S. Typhi-infected autologous blasts or S. Typhi-infected 
AEH cells (the latter to measure HLA-E-restricted CMI). 
PBMC were evaluated using 14-color multiparametric 
flow cytometry and CD8+ T cells were divided based 
on their expression of CD62L and CD45RA into naïve 
T (TN; CD62L+CD45RA+), T central memory (TCM; 
CD62L+CD45RA−), T effector memory (TEM; CD62L−
CD45RA−), and T effector memory CD45RA+ (TEMRA; 
CD62L−CD45RA+) subsets. No significant differences 
were observed at baseline between the TD and NoTD 
groups in the absolute number of white cells, lympho-
cytes, CD3, CD8 and CD4 memory subsets (Additional 
file 1: Figure S1). S. Typhi-specific responses were further 
characterized by co-expression of the T cell activation 
marker CD69 and the cytotoxicity degranulation marker 
CD107a, as well as the production of IFN-γ, TNF-α, 
MIP-1β, IL-17A and IL-2.
Most participants who did not develop infection 
(NoTD) showed higher S. Typhi-specific TEM and TEMRA 
responses at baseline than participants diagnosed with 
typhoid disease (TD) (Fig. 1). Since these differences were 
observed after stimulation with the different S. Typhi-
infected cells, we combined them for the analyses shown 
in Fig.  1. Consistent with our previous findings [17, 19, 
20, 24], TEM cells (TEM and TEMRA) represented the major 
subsets exhibiting intracellular chemokine/cytokine pro-
duction. Significant differences were observed between 
the TD and NoTD groups for the expression of CD107a 
in TEM, as well as the production of TNF-α, MIP-1β and 
IL-2 in TEM and TEMRA. Similar trends, albeit not sig-
nificant, were also observed in CD107a expression and 
IFN-γ production by TEMRA and IL-17A production by 
TEM, TEMRA and TCM. No differences were observed in 
the TCM subset, except for IL-17A production but this 
difference did not reach significance.
Interestingly, among the volunteers diagnosed with 
typhoid, we also found a positive relationship (significant 
in many cases) between S. Typhi-specific baseline levels 
of all markers in TEM and delay in time of disease onset 
(Fig. 2). These relationships were significant for CD107a 
expression, and IFN-γ and MIP-1β production. These 
data show that the presence of higher levels of S. Typhi-
specific T cells before challenge were associated with 
protection against typhoid fever and delayed time to dis-
ease onset.
Distinct clinical outcomes are accompanied by discrete S. 
Typhi‑specific responses after challenge
After identifying correlations between baseline responses 
and clinical outcome, we examined the kinetics of 
immune responses until day 28 after challenge. Decreases 
in the absolute numbers of CD3+, CD8+ were observed 
in TD participants before diagnosis (Additional file  1: 
Figure S2A), a finding consistent with the decreased lym-
phocyte counts previously reported [3]. Decreases in the 
absolute numbers of S. Typhi-specific TEM expressing 
CD107a and cytokine-producing cells were also observed 
(Additional file 1: Figure S2B) in TD subjects. In contrast, 
these decreases in the absolute numbers of S. Typhi-spe-
cific TEM expressing CD107a or producing IFN-γ were 
not observed in NoTD participants (Additional file  1: 
Figure S2B). We also investigated whether challenge with 
wt S. Typhi elicited multiphasic responses such as those 
observed after vaccination with Ty21a [19, 20]. Soon fol-
lowing challenge and before the onset of disease, 5 out of 
6 TD evaluable participants showed a decrease in circu-
lating CD107a-expressing and cytokine-producing TEM 
cells following stimulation with S. Typhi-infected B-EBV 
cells (Fig. 3a, Additional file 1: Figure S3A). In most TD 
subjects, this early drop was followed by a sharp rebound 
above baseline levels after disease onset. In contrast, 
no changes were observed in 4 out of the 6 NoTD par-
ticipants (Additional file 1: Figure S3A). Of note, in three 
NoTD participants who did not reach the criteria for 
typhoid disease diagnosis, S. Typhi was detected either 
in blood by PCR or in stool (Additional file  1: Figure 
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Fig. 1 Baseline S. Typhi-specific CD8+ T cell responses define the clinical outcome after challenge. PBMC isolated at baseline from each partici-
pant (TD n = 7, blue; NoTD n = 9, red) were stimulated for 18 h with S. Typhi-infected AEH cells (squares), S. Typhi-infected B-EBV cells (circles) or S. 
Typhi-infected blasts (triangles). After co-culture, cells were immunostained with a 14-color panel of mAbs and analyzed by follow cytometry as 
described in Methods. Each symbol represents the net percentage of positive cells measured for CD107a, IFN-γ, TNF-α, MIP-1β, IL-17A and IL-2 in the 
CD8+ TEM, TEMRA and TCM subsets as indicated for each participant. Horizontal lines represent the median for each group. Statistical analyses were 
performed using mixed effects models to account for multiple observations per person. *p < 0.05, **p < 0.01
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S3A). Interestingly, these NoTD volunteers showed simi-
lar decreases after challenge to those observed in TD 
volunteers. Of note, variability in the magnitude of the 
decrease after challenge was noticed among TD par-
ticipants (Additional file 1: Figure S3A). We identified a 
positive trend for all biomarkers between the magnitude 
of the decrease below baseline (area under the curve 
(AUC)) and their baseline levels. Significant correlations 
in these measurements were observed for IFN-γ, TNF-α, 
IL-17A and IL-2 in TEM cells (Fig. 3b). Notably, TEM cells 
showed a more pronounced decrease for all makers, fol-
lowed by TEMRA and TCM cells (Additional file 1: Figure 
S3B).
Enhanced gut homing potential of S. Typhi‑specific CD8+ T 
cells in participants diagnosed with typhoid disease
The mucosal immunity elicited at the site of entry for S. 
Typhi is expected to be a key factor in protection against 
typhoid fever after vaccination with live oral typhoid 
vaccines [14, 17]. Therefore, we assessed whether the 
decrease in S. Typhi-specific responses after challenge 
were at least in part due to the selective migration of 
CD8+ T cells to the small intestine, as determined by 
the expression of the gut homing molecule integrin α4β7 
(Fig. 4a) in S. typhi-specific TEM cells. We found no dif-
ference in the baseline proportions of integrin α4β7-
expressing cells between the TD and NoTD groups in 
total CD8+ TEM cells (Fig. 4a). Interestingly, a substantial 
decline in the proportion of integrin α4β7+ CD8+ TEM 
was observed in circulation around the time of diagno-
sis (d6-d14) for TD participants, while this proportion 
remained unchanged for NoTD participants (Fig. 4b). We 
next measured the S. typhi-specific expression of integ-
rin α4β7 on activated (CD69+) CD8+ TEM after stimula-
tion with S. typhi-infected cells (AEH cells, B-EBV cells 
or blasts). Early after challenge, TD participants showed 
similar decreases in both integrin α4β7− and integ-
rin α4β7+ S. typhi-specific TEM, and both populations 
rebounded over baseline levels after disease diagnosis 
(Fig. 4c). In contrast, no changes were observed in NoTD 
participants (Fig. 4c).
S. Typhi‑specific CD8+ TM cells are primarily 
multifunctional (MF)
Concomitant production of cytokines/chemokines and/
or expression of CD107a by single cells (multifunc-
tional cells) appear to be central for protective immune 
responses [19, 20, 25–28]. Thus, we next studied the 
characteristics of all 64 possible combinations of the 
six functional biomarkers measured in CD8+ TEM cells 
at baseline. We first grouped them into single positive 
(1+) or multifunctional (MF) cells, i.e., cells positive for 
two or more biomarkers (Fig.  5a). Notably, at baseline, 
the MF populations were significantly higher in partici-
pants who did not develop typhoid disease. We further 
categorized the MF populations based on the number 
of biomarkers they exhibited, and observed that double 
(2+), triple (3+) and quadruple (4+) positive populations 
comprise the dominant populations of S. Typhi-specific 
MF CD8+ TEM in TD and NoTD participants (Fig. 5b). 
Moreover, we observed that quadruple (4+) and quin-
tuple-sextuple (5–6+) positive MF cells were signifi-
cantly higher in the NoTD group, while strong trends 
were also observed for double and triple positive cells. 
We further characterized the individual MF populations 
by identifying the six dominant (i.e., highest frequency) 
MF populations, which together represented 65–85 % of 
IFN γ
α β
-
TNF- MIP- 1
0
5
15
25
45
IL-2
0
1
2
3
IL-17A
0
0.5
1
1.5
%
 p
os
iti
ve
 c
el
ls
Time to diagnosis (hrs)
TEM
CD107a
100 200 300 400
100 200 300 400
100 200 300 400 100 200 300 400
100 200 300 400
100 200 300 400
0
5
15
30
0
5
15
30
0
5
15
35** **
**p = 0.31
p = 0.08p = 0.41
p<0.01**TD B-EBV TD blastTD AEH
Fig. 2 High levels of S. Typhi-specific CD8+ T cell responses are asso-
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to account for multiple observations per person. *p < 0.05; **p < 0.01
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the total S. Typhi-specific MF cells in the NoTD partici-
pants (Fig. 5c). The production of the chemokine MIP-1β 
was a major characteristic in all populations, followed 
by CD107a expression and production of IFN-γ and 
TNF-α while IL-2 was detected at considerably lower 
frequencies. The CD107a+IFN-γ+TNF-α+MIP-1β+, 
CD107a+TNF-α+MIP-1β+ and CD107a+MIP-1β+ 
populations were predominant and significantly higher 
in the NoTD participants. IL-17A was detected at lower 
levels, and was not produced by any of the 6 dominant 
populations. Of note, several of the dominant MF popu-
lations (e.g., CD107a+MIP-1β+) showed significant cor-
relations with delayed time to disease diagnosis. The MF 
cells were similarly dominant in both integrin α4β7− and 
integrin α4β7+ TEM in NoTD participants (Additional 
file  1: Figure S4A, B), however, the TNF-α+MIP-1β+ 
and CD107+TNF-α+MIP-1β+ populations were sig-
nificantly higher in integrin α4β7− TEM subsets (Addi-
tional file  1: Figure S4C). No differences were observed 
between integrin α4β7− TEM and integrin α4β7+ TEM in 
TD participants.
Finally, we observed that S. Typhi-specific MF 
responses were also prevalent at day 7 post challenge in 
NoTD participants (Fig.  6a, b), and no differences were 
found in the percentages of the six dominant popula-
tions compared to baseline (Fig.  6c). Interestingly, in 
contrast to what we observed before challenge, in TD 
subjects we recorded a strong trend towards a dominance 
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of MF cells 48  h after typhoid diagnosis (Fig.  6a). This 
dominance of MF populations in TD participants at 
48  h was more evident in integrin α4β7+ than in integ-
rin α4β7− S. Typhi-specific TEM subsets (Additional file 1: 
Figure S5A, B). TNF-α+MIP-1β+, CD107+MIP-1β+ 
and CD107a+IFN-γ+TNF-α+MIP-1β+ populations in 
NoTD participants were significantly higher in the inte-
grin α4β7− TEM subsets (Additional file  1: Figure S5C). 
However, no differences were observed between integrin 
α4β7− TEM and integrin α4β7+ TEM in TD participants. 
Taken together, these results point to the importance 
of MF S. Typhi-specific CD8+ TEM with gut, as well as 
extra-intestinal tissue homing potential in protection 
from disease.
Discussion
Studies on typhoid fever immunity in humans have been 
largely restricted to patients residing in endemic areas 
and subjects immunized with licensed and experimental 
typhoid vaccines. In contrast, virtually no information 
is available on the immune status, particularly regarding 
CMI, prior to infection and on the immunological corre-
lates of protection following oral exposure to wt S. Typhi. 
The re-establishment of the human challenge model with 
wt S. Typhi provided a unique opportunity to directly 
assess the impact of S. Typhi-specific CMI responses 
before pathogen exposure to the subsequent develop-
ment of, or protection from, typhoid disease. Herein we 
show that higher S. Typhi-specific baseline responses 
are associated with protection against typhoid fever 
and delayed time to diagnosis and characterized these 
responses in great detail. If confirmed by future studies 
involving additional volunteers, these novel observa-
tions suggest an important role of anti-S. Typhi specific 
multifunctional CMI responses in protection from dis-
ease. This information has the potential to greatly accel-
erate the development of novel new generation typhoid 
vaccines.
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It has been recently described that the multifunc-
tional quality of the responses is critical for protection 
against pathogens [23, 25–28]. In the current study we 
provide evidence that S. Typhi-specific MF CD8+ TEM 
and TEMRA cells are the major effector subsets asso-
ciated with protection against typhoid fever, as well 
as delayed time to disease onset. Of note, while MF S. 
Typhi-specific CD8+ cells in NoTD participants were 
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dominant both before and after challenge, this domi-
nance was seen in TD participants only after challenge. 
MIP-1β was shown to play a role in CTL activity and in 
controlling infection in HIV non-progressors [29–31]. 
We previously described the co-production of MIP-1β 
with IFN-γ, TNF-α, IL-17A and IL-2 following vacci-
nation with Ty21a [20] and MIP-1β was reported to be 
produced by PBMC obtained from S. Typhi-infected 
convalescent patients [32]. Herein, we show that produc-
tion of MIP-1β is a major feature of S. Typhi-specific MF 
populations suggesting that co-production of MIP-1β 
with other cytokines is a key component in protection 
against S. Typhi. These results highlight that a strong MF 
component of CD8+ TEM responses both at baseline and 
after challenge, is associated with disease protection and 
delayed time to diagnosis.
Following challenge we observed decreases in the per-
centages of circulating S. Typhi-specific TEM cells in TD 
participants, suggesting that these cells might be leav-
ing the systemic circulation during the incubation phase 
of the disease. Similar to the decreases in lymphocyte 
counts reported post-challenge in TD participants [3], 
we also observed a decline in the absolute numbers of 
CD3+, CD8+ and CD4+ T cells. Integrin α4β7 expres-
sion plays an essential role in the selective homing of T 
cells to the gut, the site of entry for S. Typhi [16, 33–36]. 
After challenge, TD participants show a decrease in total 
integrin α4β7+ CD8+ TEM and in both integrin α4β7− 
and α4β7+ S. Typhi-specific TEM cells. However, 48  h 
after diagnosis, the proportion of S. Typhi-specific MF 
integrin α4β7+ TEM in TD subjects was higher than in 
integrin α4β7− cells. This shift in the balance of single-
positive vs. MF S. Typhi-specific CD8+ TEM in circula-
tion might be the result of activation and expansion of 
MF S. Typhi-specific integrin α4β7+ CD8+ TEM cells due 
to the ongoing infection in the gut and other lymphoid 
tissues. Taken together, these results highlight that strong 
MF CD8+ TEM responses with the potential to home to 
the gut as well as to other lymphoid tissues are associ-
ated with disease protection and delayed time to diagno-
sis. These results complement and expand our previous 
findings showing that vaccination against S. Typhi elic-
ited integrin α4β7+ and integrin α4β7− CD8+ effector T 
cells [14, 16, 17, 24]. These observations also suggest that 
S. typhi-specific TEM cells migrate not only to mucosal 
sites, but also presumably to secondary lymphoid tis-
sues, where they may reduce S. typhi replication during 
the incubation phase, delaying disease onset. Moreover, 
post-challenge decreases in circulating S. Typhi-specific 
T cells are proportional to the levels present at baseline, 
suggesting that the higher the pool of S. Typhi-specific T 
cells available, the higher the number of these cells that 
are recruited to the sites of inflammation.
Several studies in the murine S. typhimurium model 
have shown that the balance of suppressive regulatory T 
cell (Treg) and pro-inflammatory T cell responses influ-
ence bacterial clearance or persistence [37]. We have 
recently evaluated in these challenged volunteers the 
hypothesis that the development of Treg responses [38] 
following exposure to wt S. Typhi could be responsible, 
at least in part, for the decrease of S. Typhi-specific TEM 
responses. We observed that TD participants exhibited 
up-regulation of the gut homing molecule integrin α4β7 
pre-challenge, followed by a significant down-regulation 
post-challenge consistent with Treg homing to the gut, 
as well as up-regulation of activation molecules post-
challenge. We also showed that depletion of Treg results 
in increased S. Typhi-specific cytokine production by 
CD8+ TEM in vitro. These observations suggest that the 
tissue distribution of activated Treg, their characteristics 
and activation status may play a key role in typhoid fever, 
possibly through suppression of S. Typhi-specific effector 
T cell responses [39].
In contrast to the results seen in TD participants, we 
observed that protection against typhoid fever is mostly 
associated with very low or no changes in circulating S. 
Typhi-specific TM after challenge. Of note, several of the 
few NoTD participants showing decreases in S. Typhi-
specific TEM were PCR positive or stool positive par-
ticipants despite the fact that they did not meet typhoid 
disease diagnosis. These findings suggest that the control 
and clearance of S. Typhi in NoTD participants might 
be driven by innate and/or adaptive immune responses 
in the gut microenvironment, precluding S. Typhi from 
becoming invasive and causing disease. However, the 
underlying mechanism(s) of control of S. Typhi infection 
in the gut microenvironment remain unclear. “Innate-
like” T cell types such as TCRγ/δ T cells, NK-T cells and 
mucosal associated invariant T (MAIT) cells might be 
involved in protection from typhoid disease. MAIT cells 
are comprised of CD8+CD4− and CD8−CD4− subsets 
restricted by the MR1 MHC-related molecule which are 
widely believed to play an important in mucosal immu-
nity [40]. We have recently shown that MAIT cells from 
healthy individuals are able to produce IL-17A, IFN-γ 
and TNF-α when exposed to S. Typhi-infected cells [41]. 
Ongoing experiments directed to characterize MAIT cell 
responses in the challenged participants are expected to 
shed light into the role of these cells following exposure 
to wt S. Typhi.
Because of the very limited data available regarding 
immune responses prior to typhoid infection, the reasons 
for the disparity in baseline responses observed among 
the participants are unclear. Participants were recruited 
in the UK, a non-endemic region, have not been vacci-
nated against typhoid, and therefore have likely never 
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encountered S. Typhi. However, differences in base-
line responses could be due to cross-reactive memory 
responses elicited by previous exposure to other Sal-
monella serovars [42–44], or other Enterobacteriaceae, 
including those present in the normal gut microbiota [22, 
45–47]. Several studies highlight the importance of the 
gut microbiota in modulating host immune responses to 
pathogens or to vaccination [45–47]. We have recently 
shown that vaccination against S. Typhi caused no altera-
tions of the microbiota, however, individuals displaying 
early multiphasic CMI responses harbored more diverse 
communities than late responders [47]. We have initi-
ated studies to identify the interplay between the host 
immune response, the microbiota and clinical outcome 
in volunteers challenged with wt S. Typhi. In addition 
to these acquired immune response differences, genetic 
determinants like HLA molecules can also be critical in 
defining the variation in immune responses. For example, 
the presence of the HLA-DRB1*04:05 allele was recently 
associated with protection against S. Typhi [48].
Conclusions
In summary, we have provided the first direct evidence 
of an association between higher baseline levels of multi-
functional S. Typhi-specific CD8+ T cells and protection, 
as well as delayed time to disease onset, in an oral chal-
lenge model with wt S. Typhi in humans. These studies 
also revealed some of the immunological responses asso-
ciated with delayed time to disease onset and defined the 
homing characteristics of the S. Typhi-specific effector 
and memory CD8+ T cell populations. This information 
supports the performance of in depth CMI measure-
ments to aid in the early selection of novel vaccine can-
didates for further development and evaluation in clinical 
trials.
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IFN-γ production by CD8+ TEM following stimulation with S. Typhi-infected 
B-EBV cells are presented for each participant. The day at which each of 
the TD participants was diagnosed is indicated after their id number. (b) 
Areas under the curve were measured around the time of diagnosis for 
each biomarker in CD8+ TEM, TEMRA and TCM subsets. Each bar represents 
mean ± SEM of area under the curve obtained after stimulation with 
S. Typhi-infected AEH cells, B-EBV cells and blasts. Figure S4. Homing 
potential of the dominant S. Typhi-specific CD8+ TEM multifunctional 
populations at baseline. Flow cytometry data were analyzed using the 
FCOM function of Winlist to determine the proportion of all possible com-
binations of the six measured biomarkers to identify MF cells (i.e., positive 
for multiple biomarkers concomitantly). Each symbol represents the 
percentage of the different populations measured after stimulation with 
S. Typhi-infected cells (AEH cells [squares], B-EBV [circles] cells or blasts 
[triangles]) for each participant. (a) The percentages of single positive cells 
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responses in TD and NoTD participants after challenge. Flow cytometry 
data were analyzed using the FCOM function of Winlist to determine the 
proportion of all possible combinations of the six measured biomarkers 
to identify MF cells (i.e., positive for several biomarkers concomitantly). 
Percentages were measured at day 7 for NoTD participants and at 48 h 
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S. typhi-infected cells (AEH cells [squares], B-EBV [circles] cells or blasts 
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*p < 0.05, **p < 0.01, ***p < 0.001.
Page 13 of 14Fresnay et al. J Transl Med  (2016) 14:62 
University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, 
UK. 4 Nuffield Department of Medicine, University of Oxford, Oxford, UK. 
Acknowledgements
This work was funded, in part, by a Strategic Translation award from the 
Wellcome Trust [grant number 092661], the NIHR Oxford Biomedical Research 
Centre [Clinical Research Fellowships to CSW and TCD], the Jenner Institute, 
the Oxford Martin School, the European Union [FP7, Marie Curie Research 
Fellowship to CJB], by NIAID, NIH, DHHS grants R01-AI036525, U19 AI082655 
(CCHI) and U19-AI109776 (Center of Excellence for Translational Research 
[CETR], and a Passano Foundation Clinical Investigator Award (to MAM). 
SF was funded in part by NIH Fellowship Training Program in Vaccinology 
T32-AI07524. The content is solely the responsibility of the authors and does 
not necessarily represent the official views of the National Institute of Allergy 
and Infectious Diseases, the National Institutes of Health, the National Health 
Service, the National Institute for Health Research (NIHR) or the UK Depart-
ment of Health.
Competing interests
The authors declare that they have no competing interests.
Received: 24 September 2015   Accepted: 17 February 2016
References
 1. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid Fever. Clin 
Infect Dis. 2010;50:241–6.
 2. Dougan G, Baker S. Salmonella enterica serovar typhi and the pathogen-
esis of typhoid fever. Annu Rev Microbiol. 2014;68:317–36.
 3. Waddington CS, Darton TC, Jones C, Haworth K, Peters A, John T, Thomp-
son BA, Kerridge SA, Kingsley RA, Zhou L, et al. An outpatient, ambulant-
design, controlled human infection model using escalating doses of 
Salmonella Typhi challenge delivered in sodium bicarbonate solution. 
Clin Infect Dis. 2014;58:1230–40.
 4. Darton TC, Blohmke CJ, Pollard AJ. Typhoid epidemiology, diagnostics 
and the human challenge model. Curr Opin Gastroenterol. 2014;30:7–17.
 5. Levine MM, Tacket CO, Sztein MB. Host-Salmonella interaction: human 
trials. Microbes Infect. 2001;3:1271–9.
 6. Hornick RB, Woodward WE, Greisman SE. Doctor T. E. Woodward’s legacy: 
from typhus to typhoid fever. Clin Infect Dis. 2007;45(Suppl 1):S6–8.
 7. Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder 
MJ. Typhoid fever: pathogenesis and immunologic control. N Engl J Med. 
1970;283:686–91.
 8. Woodward WE. Volunteer studies of typhoid fever and vaccines. Trans R 
Soc Trop Med Hyg. 1980;74:553–6.
 9. Hornick RB, Woodward TE. Appraisal of typhoid vaccine in experimentally 
infected human subjects. Trans Am Clin Climatol Assoc. 1967;78:70–8.
 10. Salerno-Goncalves R, Pasetti MF, Sztein MB. Characterization of CD8(+) 
effector T cell responses in volunteers immunized with Salmonella 
enterica serovar typhi strain Ty21a typhoid vaccine. J Immunol. 
2002;169:2196–203.
 11. Sztein MB, Tanner MK, Polotsky Y, Orenstein JM, Levine MM. Cytotoxic T 
lymphocytes after oral immunization with attenuated vaccine strains of 
Salmonella typhi in humans. J Immunol. 1995;155:3987–93.
 12. Salerno-Goncalves R, Wyant TL, Pasetti MF, Fernandez-Vina M, Tacket CO, 
Levine MM, Sztein MB. Concomitant induction of CD4+ and CD8+ T cell 
responses in volunteers immunized with Salmonella enterica serovar typhi 
strain CVD 908-htrA. J Immunol. 2003;170:2734–41.
 13. Salerno-Goncalves R, Fernandez-Vina M, Lewinsohn DM, Sztein MB. Iden-
tification of a human HLA-E-restricted CD8 + T cell subset in volunteers 
immunized with Salmonella enterica serovar typhi strain Ty21a typhoid 
vaccine. J Immunol. 2004;173:5852–62.
 14. Salerno-Goncalves R, Wahid R, Sztein MB. Immunization of volunteers 
with Salmonella enterica serovar typhi strain Ty21a elicits the oligoclonal 
expansion of CD8+ T cells with predominant Vbeta repertoires. Infect 
Immun. 2005;73:3521–30.
 15. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. Cell-
mediated immune responses in humans after immunization with one 
or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine. 
2007;25:1416–25.
 16. Sztein MB. Cell-mediated immunity and antibody responses elicited by 
attenuated Salmonella enterica Serovar typhi strains used as live oral vac-
cines in humans. Clin Infect Dis. 2007;45(Suppl 1):S15–9.
 17. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. Genera-
tion of specific effector and memory T cells with gut- and secondary 
lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid 
vaccine in humans. Mucosal Immunol. 2008;1:389–98.
 18. Salerno-Goncalves R, Sztein MB. Priming of Salmonella enterica serovar 
typhi-specific CD8(+) T cells by suicide dendritic cell cross-presentation 
in humans. PLoS ONE. 2009;4:e5879.
 19. Salerno-Goncalves R, Wahid R, Sztein MB. Ex Vivo kinetics of early and 
long-term multifunctional human leukocyte antigen E-specific CD8+ 
cells in volunteers immunized with the Ty21a typhoid vaccine. Clin Vac-
cine Immunol. 2010;17:1305–14.
 20. McArthur MA, Sztein MB. Heterogeneity of multifunctional IL-17A 
producing S. typhi-specific CD8 + T cells in volunteers following Ty21a 
typhoid immunization. PLoS ONE. 2012;7:e38408.
 21. Sztein MB, Wasserman SS, Tacket CO, Edelman R, Hone D, Lindberg 
AA, Levine MM. Cytokine production patterns and lymphoproliferative 
responses in volunteers orally immunized with attenuated vaccine strains 
of Salmonella typhi. J Infect Dis. 1994;170:1508–17.
 22. Sztein MB, Salerno-Goncalves R, McArthur MA. Complex adaptive immu-
nity to enteric fevers in humans: lessons learned and the path forward. 
Front Immunol. 2014;5:516.
 23. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, 
Koup RA. Sensitive and viable identification of antigen-specific CD8+ T 
cells by a flow cytometric assay for degranulation. J Immunol Methods. 
2003;281:65–78.
 24. Wahid R, Fresnay S, Levine MM, Sztein MB. Immunization with Ty21a live 
oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell 
responses against Salmonella enterica serovar typhi, S. Paratyphi A, and S. 
Paratyphi B in humans. Mucosal Immunol. 2015.
 25. Rozot V, Vigano S, Mazza-Stalder J, Idrizi E, Day CL, Perreau M, Lazor-
Blanchet C, Petruccioli E, Hanekom W, Goletti D, et al. Mycobacterium 
tuberculosis-specific CD8+ T cells are functionally and phenotypically 
different between latent infection and active disease. Eur J Immunol. 
2013;43:1568–77.
 26. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: 
implications for vaccine design. Nat Rev Immunol. 2008;8:247–58.
 27. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, 
Andersen P, Reed SG, Morris SL, et al. Multifunctional TH1 cells define a 
correlate of vaccine-mediated protection against Leishmania major. Nat 
Med. 2007;13:843–50.
 28. Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz 
NM, Hu Z, Joshi G, Ploquin A, Sitar S, et al. Chimpanzee adenovirus vector 
ebola vaccine—preliminary report. N Engl J Med. 2014.
 29. Kim JJ, Nottingham LK, Sin JI, Tsai A, Morrison L, Oh J, Dang K, Hu Y, Kaza-
haya K, Bennett M, et al. CD8 positive T cells influence antigen-specific 
immune responses through the expression of chemokines. J Clin Invest. 
1998;102:1112–24.
 30. Makedonas G, Betts MR. Polyfunctional analysis of human t cell 
responses: importance in vaccine immunogenicity and natural infection. 
Springer Semin Immunopathol. 2006;28:209–19.
 31. Kutscher S, Dembek CJ, Allgayer S, Heltai S, Stadlbauer B, Biswas P, Nozza 
S, Tambussi G, Bogner JR, Stellbrink HJ, et al. The intracellular detection 
of MIP-1beta enhances the capacity to detect IFN-gamma mediated 
HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing 
a sensitive alternative to the ELISPOT. AIDS Res Ther. 2008;5:22.
 32. Bhuiyan S, Sayeed A, Khanam F, Leung DT, Rahman Bhuiyan T, Sheikh 
A, Salma U, LaRocque RC, Harris JB, Pacek M, et al. Cellular and cytokine 
responses to Salmonella enterica serotype typhi proteins in patients with 
typhoid fever in Bangladesh. Am J Trop Med Hyg. 2014;90:1024–30.
 33. Lundin BS, Johansson C, Svennerholm AM. Oral immunization with a 
Salmonella enterica serovar typhi vaccine induces specific circulating 
mucosa-homing CD4(+) and CD8(+) T cells in humans. Infect Immun. 
2002;70:5622–7.
Page 14 of 14Fresnay et al. J Transl Med  (2016) 14:62 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 34. Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal 
vaccines. Immunol Rev. 2011;239:125–48.
 35. Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol. 
2008;29:514–22.
 36. Mora JR, von Andrian UH. T-cell homing specificity and plas-
ticity: new concepts and future challenges. Trends Immunol. 
2006;27:235–43.
 37. Johanns TM, Ertelt JM, Rowe JH, Way SS. Regulatory T cell suppres-
sive potency dictates the balance between bacterial proliferation 
and clearance during persistent Salmonella infection. PLoS Pathog. 
2010;6:e1001043.
 38. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev 
Immunol. 2007;7:875–88.
 39. McArthur MA, Fresnay S, Magder LS, Darton TC, Jones C, Waddington CS, 
Blohmke CJ, Dougan G, Angus B, Levine MM, et al. Activation of salmo-
nella typhi-specific regulatory T cells in typhoid disease in a wild-type S. 
typhi challenge model. PLoS Pathog. 2015;11:e1004914.
 40. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, Core M, Levy E, Dus-
seaux M, Meyssonnier V, Premel V, et al. Antimicrobial activity of mucosal-
associated invariant T cells. Nat Immunol. 2010;11:701–8.
 41. Salerno-Goncalves R, Rezwan T, Sztein MB. B cells modulate mucosal 
associated invariant T cell immune responses. Front Immunol. 2014;4:511.
 42. McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney 
L, Porwollik S, Ali J, Dante M, Du F, et al. Complete genome sequence of 
Salmonella enterica serovar typhimurium LT2. Nature. 2001;413:852–6.
 43. Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. Live oral typhoid vac-
cine Ty21a induces cross-reactive humoral immune responses against 
Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin 
Vaccine Immunol. 2012;19:825–34.
 44. Pakkanen SH, Kantele JM, Herzog C, Kantele A. Cross-reactive immune 
response elicited by parenteral Vi polysaccharide typhoid vaccine against 
non-typhoid Salmonellae. Vaccine. 2014;32:544–51.
 45. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflamma-
tion. Cell. 2014;157:121–41.
 46. Ferreira RB, Antunes LC, Finlay BB. Should the human microbiome be 
considered when developing vaccines? PLoS Pathog. 2010;6:e1001190.
 47. Eloe-Fadrosh EA, McArthur MA, Seekatz AM, Drabek EF, Rasko DA, 
Sztein MB, Fraser CM. Impact of oral typhoid vaccination on the human 
gut microbiota and correlations with S. typhi-specific immunological 
responses. PLoS One. 2013;8:e62026.
 48. Dunstan SJ, Hue NT, Han B, Li Z, Tram TT, Sim KS. Variation at HLA-DRB1 is 
associated with resistance to enteric fever. 2014.
